Upstream Bio, Inc. (UPB)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $152.38M
Last updated: Nov 17, 2026 at 11:05 AM ET
Upstream Bio, Inc. (UPB) Stock Forecast
Analysts expect Upstream Bio (UPB) to earn -$2.96 per share in the fiscal year ending Dec 31, 2026, on revenue of $2.47M. Of 8 analysts, 6 rate the stock Buy or Strong Buy, 2 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 5 estimates for the fiscal year ending Dec 31, 2026 were revised up and 3 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 8 ratings average 2.13, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 75% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 12.5% |
| Buy | 5 | 62.5% |
| Hold | 2 | 25.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 8
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates fall 52.6%.
- Fiscal year ending Dec 31, 2026
- -$2.96
- EPS consensus, revenue $2.47M
- Fiscal year ending Dec 31, 2027
- -$2.63
- EPS consensus, revenue $1.17M
- Next report
- Mar 24, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$2.96 | -$3.12 to -$2.81 | 7 | $2.47M | $2.20M to $3.00M | 6 |
| Dec 31, 2027 | -$2.63 | -$3.40 to -$1.77 | 6 | $1.17M | N/A | 5 |
Quarterly Estimates
The EPS consensus falls from -$0.72 for the quarter ending Dec 31, 2026 to -$0.79 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.72 | -$0.93 to -$0.44 | 8 | $431270 | N/A | 8 |
| Mar 31, 2027 | -$0.79 | -$1.03 to -$0.61 | 4 | $135670 | N/A | 3 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 10 upward and 7 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 5 | 3 |
| Fiscal year ending Dec 31, 2027 | 3 | 3 |
| Quarter ending Mar 31, 2027 | 2 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$2.99.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$2.96 | -$2.90 | -$2.90 | -$2.90 | -$2.99 | N/A |
| Fiscal year ending Dec 31, 2027 | -$2.63 | -$2.80 | -$2.80 | -$2.80 | -$2.90 | N/A |
| Quarter ending Mar 31, 2027 | -$0.79 | -$0.77 | -$0.77 | -$0.77 | -$0.88 | N/A |
Frequently Asked Questions About UPB
What is the UPB stock forecast?
Consensus analyst estimates put Upstream Bio's EPS at -$2.96 for the fiscal year ending Dec 31, 2026, on revenue of $2.47M. The consensus rating from 8 analysts is Buy.
How do analysts rate UPB stock?
Of 8 analysts covering Upstream Bio, 1 rates it Strong Buy, 5 Buy, 2 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from UPB next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$2.96, with estimates from -$3.12 to -$2.81 from 7 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$2.63, with estimates from -$3.40 to -$1.77 from 6 analysts.
What revenue do analysts expect from Upstream Bio next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $2.47M, with estimates from $2.20M to $3.00M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $1.17M.
How many analysts cover UPB?
8 analysts rate Upstream Bio stock, and 7 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
UPB pages: Overview, Earnings, Forecast, Financials, Competitors